OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

Amsterdam University Medical Centres VU University Medical Centre Department Rheumatology and Immunology Center Amsterdam Netherlands

biorx si and the Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Centre for Rheumatology Research University Hospital and Faculty of Medicine University of Iceland Reykjavik Iceland

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup Copenhagen Denmark

DANBIO Registry Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup Copenhagen Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology and Inflammation Research Institute of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Department of Rheumatology Diakonhjemmet Hospital Oslo Norway

Department of Rheumatology Geneva University Hospital Geneve Switzerland

Department of Rheumatology Izmir Kâtip Çelebi University Izmir Turkey

Department of Rheumatology Landspitali University Hospital Reykjavik Iceland

Department of Rheumatology University Hospital Zurich Zurich Switzerland

Division of Rheumatology Department of Medicine Hospital of Southern Norway Trust Kristiansand Norway

Epidemiology Group School of Medicine Medical Science and Nutrition University of Aberdeen Aberdeen UK

GISEA Registry Rheumatology Unit DETO University of Bari Bari Italy

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Research Unit Spanish Society of Rheumatology Madrid Spain

Reuma pt Registry and Instituto De Medicina Molecular Faculdade De Medicina Universidade De Lisboa Lisboa Lisboa Portugal

Reuma pt registry and Instituto Português de Reumatologia Lisbon Portugal

Rheumatology Service Hospital Clinico Universitario Santiago De Compostela Spain

Rheumatology Unit CHIMOMO Azienda Policlinico of Modena University of Modena Modena Italy

ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland

TURKBIO Registry Division of Rheumatology Dokuz Eylul University School of Medicine Izmir Turkey

University of Medicine and Pharmacy Carol Davila Bucharest Bucharest Romania

Zobrazit více v PubMed

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73–84. 10.1016/S0140-6736(16)31591-4 PubMed DOI

Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17. 10.1136/annrheumdis-2017-211734 PubMed DOI PMC

van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2016;2017:978–91. 10.1136/annrheumdis-2016-210770 PubMed DOI

Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705–13. 10.1016/S0140-6736(13)61134-4 PubMed DOI

Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534–48. 10.1056/NEJMoa1505066 PubMed DOI

Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open 2017;3:e000592 10.1136/rmdopen-2017-000592 PubMed DOI PMC

Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017;19:285 10.1186/s13075-017-1490-y PubMed DOI PMC

Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis 2016;75:408–12. 10.1136/annrheumdis-2015-207544 PubMed DOI

Gentileschi S, Rigante D, Sota J, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm 2020;2020:6983272 10.1155/2020/6983272 PubMed DOI PMC

Williams T, Wadeley A, Bond D, et al. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. Clin Rheumatol 2020;39:1501–4. 10.1007/s10067-020-04944-5 PubMed DOI

Ornbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis 2019;78:1536–44. 10.1136/annrheumdis-2019-215427 PubMed DOI

Brahe CH, Ornbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford) 2019. 10.1093/rheumatology/kez427 PubMed DOI

Michelsen B, Ornbjerg LM, Kvien TK, et al. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology (Oxford) 2020. 10.1093/rheumatology/kez656 PubMed DOI

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91. PubMed

Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5. PubMed

Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-Endorsed Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24. 10.1136/ard.2008.094870 PubMed DOI

Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45. 10.1002/art.1780230202 PubMed DOI

Landewe R, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep 2015;17:47 10.1007/s11926-015-0522-3 PubMed DOI PMC

Machado PM, Landewé R, van der Heijde D. Landewé R and van der Heijde D. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 2018;77:1539–40. 10.1136/annrheumdis-2018-213184 PubMed DOI

Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86. 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F PubMed DOI

van der Heijde D, Dougados M, Davis J, et al. Assessment in Ankylosing Spondylitis International Working Group/spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386–94. 10.1002/art.20790 PubMed DOI

Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53. 10.1136/ard.2010.138594 PubMed DOI

Kristensen LE, Saxne T, Geborek GP. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600–6. 10.1002/art.21570 PubMed DOI

Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596–602. 10.1136/ard.2009.125526 PubMed DOI

Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017;76:1070–7. 10.1136/annrheumdis-2016-209730 PubMed DOI

Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002–8. 10.1136/ard.2009.124446 PubMed DOI

Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 2017;47:343–50. 10.1016/j.semarthrit.2017.04.005 PubMed DOI

Baraliakos X, Østergaard M, Gensler LS, et al. Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig 2020;40:269–78. 10.1007/s40261-020-00886-7 PubMed DOI

Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the swiss clinical quality management cohort. Ann Rheum Dis 2020;79:1203–9. 10.1136/annrheumdis-2019-215934 PubMed DOI

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching

Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration